Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerBilling CodesGenomic Sequencing Procedures and Other Molecular Multianalyte AssaysCPT cpt-81464-liquid-biopsy-plasma-genomic-sequencing-solid-tumor
    Ask Trek AI about this page

    CPT 81464: Plasma cfDNA Genomic Sequencing for Solid Tumors

    Commercial payers pay $2689 on average nationally for this procedure.

    CPT code 81464 describes a liquid biopsy genomic sequencing procedure performed on a plasma specimen to analyze cell-free DNA (cfDNA) and DNA/RNA for sequence variants, copy number variants, and rearrangements relevant to solid organ neoplasms; the test also assesses biomarkers such as microsatellite instability (MSI) and tumor mutation burden (TMB). Service type: genomic sequencing for somatic alterations; typical site of service: clinical laboratory/diagnostic laboratory or outpatient specimen collection.

    For related coverage guidance, see recent payer policy updates: Minimal Residual Disease (MRD) Testing for Cancer, Biomarker Testing Mandate, Prenatal (Fetal) Diagnostic Testing.

    Customize your policy alerts

    Sign up for cpt 81464 policy alerts

    Get alerted when payer policies referencing 81464 are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    National Reimbursement Benchmarks

    National commercial reimbursement for CPT 81464 centers near the BUCA average commercial rate of $2,688.90, with notable differences across major carriers. Blue Cross Blue Shield shows the highest dispersion between its 25th and 75th percentiles ($1,717.70), indicating wide variability in negotiated rates; Cigna and Aetna have moderate spreads of $2,144.40 and $1,097.00 respectively. UnitedHealth Group’s interquartile spread is $1,907.30, also reflecting substantial variability, while BUCA’s IQR is $1,717.00 and thus aligns closely with Blue Cross Blue Shield in dispersion.

    Looking at central tendency, Cigna’s median ($2,946.50) and Blue Cross Blue Shield’s median ($2,572.30) sit above the BUCA mean, while UnitedHealth Group’s median ($1,973.10) falls below. Minimum-to-maximum ranges exist for Aetna, Blue Cross Blue Shield, Cigna, and UnitedHealth Group per the provided values, underscoring that list extremes can differ markedly even when averages cluster near the BUCA commercial benchmark of $2,688.90.

    National Payer Mean Reimbursement Rates

    Table of contents

    Progress1 / 8

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • Facility ComparisonBeds, revenue & payer mix
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    State Reimbursement Rates

    State: Alaska1 / 51

    Rate by payer

    Clinical & Coding Specifications

    Clinical Context

    A 62-year-old patient with a history of an oropharyngeal mass presents after biopsy-confirmed squamous cell carcinoma of the base of tongue. The oncology team requests a plasma-based liquid biopsy to profile tumor-derived cell-free DNA/RNA to identify somatic sequence variants, copy number alterations, gene rearrangements, microsatellite instability (MSI), and tumor mutational burden (TMB) to help inform systemic therapy selection and eligibility for targeted agents or immunotherapy. Peripheral blood is collected into an appropriate cfDNA-stabilizing tube during a routine oncology clinic visit. The specimen is shipped to a CLIA-certified molecular laboratory. The laboratory performs nucleic acid extraction, next-generation sequencing-based genomic analysis calibrated for plasma cfDNA, bioinformatic variant calling for single-nucleotide variants, insertions/deletions, copy number changes, and rearrangements, and calculates MSI and TMB metrics. A molecular pathologist or laboratory director reviews results, generates an interpretive report with clinically relevant alterations, and posts results to the electronic medical record and tumor board for multidisciplinary review. Billing for the assay is submitted using 81464 with applicable modifiers and the primary diagnosis code for the patient’s malignant neoplasm of tongue (for example, C01).

    Related CPT Codes

    CPT CodeDescriptionRelationship to This Procedure
    81455

    Related Modifiers

    8 rows

    ModifierDescriptionWhen to Use
    26Modifier 26 (Professional Component) identifies and bills only the professional portion of a split service — the physician’s interpretation, report, and medical judgment — when the technical…- Use CPT Modifier -26 when you are billing only the professional component (PC) of a split‑bill eligible service—i.e., you performed the physician interpretation, medical judgment and prepared a…
    52Modifier ‑52 (Reduced Services) indicates that a service or procedure was partially reduced or omitted at the provider’s discretion, allowing reporting of the basic procedure number with a qualifier…- Use modifier -52 when a physician or qualified health professional electively reduces or omits part of a procedure or service (for example, performing fewer required views or omitting a portion of…
    53Modifier 53 (Discontinued Procedure) signals that a surgical or diagnostic service was begun by the physician but terminated because of extenuating circumstances that threatened the patient’s…- Use modifier -53 when a physician/qualified healthcare professional has started a surgical or diagnostic procedure (e.g., anesthesia administered, incision or scope insertion) and then discontinues…
    62Modifier 62 indicates that two surgeons function as co‑surgeons, each performing distinct parts of the same primary surgical procedure. It is appended to the primary procedure code (and any…- Use modifier -62 when two surgeons act as co‑surgeons (both primary surgeons) on a single definitive primary procedure, each performing distinct parts of the same surgical procedure (append -62 to…
    78CPT modifier -78 indicates an unplanned, related return to the operating or procedure room by the same provider during the global postoperative period. It is appended when treatment for a…- Use modifier -78 when an unplanned, related complication during the original procedure’s global postoperative period requires the patient to return to a formal operating or procedure room and the…
    80CPT® Modifier 80 (Assistant Surgeon) is appended to a surgical CPT code when a physician (MD or DO) provides full, continuous assistance throughout the operative procedure. It is intended only for…- Use CPT Modifier -80 when a physician (MD or DO) serves as an assistant surgeon and provides full, continuous assistance throughout the entire operative procedure; append -80 to the surgical CPT…
    82Modifier 82 is appended to a surgical CPT code to indicate that an attending physician acted as an assistant because a qualified resident surgeon was unavailable. In teaching hospitals it documents…- When to use: Append modifier 82 in teaching-hospital settings to indicate a physician served as an assistant surgeon because a qualified resident surgeon was unavailable (includes situations where…
    90Modifier ‑90 (Reference/Outside Laboratory) indicates that a laboratory test was performed by an entity other than the treating or reporting provider. The American Medical Association defines…- Use CPT modifier -90 when a laboratory test is performed by an outside/reference laboratory (an entity other than the treating or reporting physician or qualified professional) and the claim needs…

    Related Provider Taxonomies

    8 rows

    Taxonomy Code
    207SG0201X
    207SG0202X
    2471C1106X
    2084F0202X
    146L00000X
    172A00000X
    204F00000X
    193200000X

    Related Payer Policy Updates

    Specialty: Genetic & Molecular Testing1 / 3

    10 rows

    PolicyPayerEffective Date
    Minimal Residual Disease (MRD) Testing for Cancerregence2027-01-01
    Biomarker Testing MandateBlue Cross Blue Shield - Rhode Island2027-01-01
    Prenatal (Fetal) Diagnostic TestingBlue Cross Blue Shield - Rhode Island2027-01-01
    Oral Cancer Screening and TestingOscar Health2027-01-01
    RTM Testing for Alpha-1 Antitrypsin DeficiencyOscar Health2027-01-01
    Cytochrome P450 Genotype-Guided Treatment Strategy Corporate Medical Policybcbsvermont2027-01-01
    Cytochrome P450 Genotypingblue cross blue shield - tennessee2026-12-31
    Polygenic Risk ScoreBlue Cross Blue Shield - Rhode Island2026-12-01
    Gene Expression Profiling for Cutaneous MelanomaBlue Cross Blue Shield - Rhode Island2026-12-01
    Chromosomal Microarray Testing for the Evaluation of Pregnancy Lossblue_shield_of_california2026-11-01

    Related Codes

    CPT-81410-GENOMIC-PANEL-AORTIC-DISEASE

    CPT 81410: Heritable Thoracic Aortic Disease Targeted Gene Panel

    CPT-81411-GENETIC-DUPLICATION-DELETION-PANEL-AORTIC-DISEASE

    CPT 81411: Genetic Panel for Aortic Dysfunction Copy Number Analysis

    CPT-81412-ASHKENAZI-JEWISH-GENOMIC-SEQUENCE-PANEL

    CPT 81412: Ashkenazi Jewish–Associated Genetic Sequence Panel

    CPT-81413-GENOMIC-PANEL-CARDIAC-ION-CHANNELOPATHIES

    CPT 81413: Cardiac Ion Channelopathy Targeted Gene Panel

    CPT-81414-CARDIAC-ION-CHANNELOPATHY-CNV-PANEL

    CPT 81414: Cardiac Ion Channelopathy Copy Number Variant Panel

    CPT-81415-EXOME-SEQUENCE-ANALYSIS-UNEXPLAINED-DISORDER

    CPT 81415: Exome Sequence Analysis for Unexplained Disorder

    CPT-81416-FAMILIAL-EXOME-SEQUENCE-ANALYSIS

    CPT 81416: Relative Exome Sequence Analysis for Reference Exome

    CPT-81417-EXOME-SEQUENCE-REEVALUATION

    CPT 81417: Exome Reanalysis for New Clinical Information

    CPT-81418-PHARMACOGENOMIC-MULTIGENE-DRUG-METABOLISM-PANEL

    CPT 81418: Pharmacogenetic Multigene Panel Including CYP2C19 and CYP2D6

    CPT-81419-GENOMIC-SEQUENCE-PANEL-EPILEPSY

    CPT 81419: Genomic Sequence Analysis Panel for Epilepsy

    Showing 1–10 of 43

    Frequently Asked Questions

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

    Genomic sequencing procedures for somatic alterations in neoplasms (other context)
    Alternative or complementary somatic sequencing methods; may be billed when tumor tissue sequencing is performed instead of or in addition to plasma cfDNA testing
    81456Genomic sequencing procedures for somatic alterations—RNA analysis separate methodUsed when separate RNA-based fusion/transcript analysis is performed in addition to DNA-based cfDNA testing
    81459Genomic sequencing procedures, multianalyte with TMB/MSI (combined analyses)Related multianalyte reporting that includes combined TMB and MSI metrics; may be billed for assays that specifically report these combined results
    0250UProprietary laboratory analysis code in same coverage groupProprietary test-specific code; relates when a vendor-specific liquid biopsy assay maps to this group
    0326UProprietary laboratory analysis code in same coverage groupAs above, another lab-specific code for related cfDNA assays
    0334UProprietary laboratory analysis code in same coverage groupAs above, vendor-specific assay code in the same coverage family
    0473UProprietary laboratory analysis code in same coverage groupAs above, additional proprietary assay code that may represent similar or complementary testing